How AI is Transforming Medication Interaction Checks: A Guide for Digital Health Professionals

Rasit Dinc

Rasit Dinc Digital Health & AI Research

Published: September 19, 2023 | AI Diagnostics

DOI: 10.5281/zenodo.17997367

Abstract

The integration of Artificial Intelligence AI into healthcare has ushered in a new era of precision medicine, with one of the most critical applications bein...

The integration of Artificial Intelligence (AI) into healthcare has ushered in a new era of precision medicine, with one of the most critical applications being the enhancement of **medication interaction checks**. Drug-Drug Interactions (DDIs) pose a significant risk to patient safety, often leading to adverse drug events (ADEs) that increase morbidity, mortality, and healthcare costs [1]. Traditional DDI screening methods, primarily relying on static databases and rule-based systems, are often overwhelmed by the sheer volume and complexity of pharmacological data, leading to alert fatigue and missed critical interactions. AI offers a transformative solution by moving beyond simple look-up tables to provide dynamic, context-aware, and predictive DDI analysis.

The Challenge of Traditional DDI Screening

Conventional DDI checking systems are foundational to modern pharmacy and clinical practice. They function by comparing a patient's medication list against a pre-compiled database of known interactions. While essential, these systems face several limitations:

1. **Data Volume and Velocity:** The number of potential drug combinations grows exponentially with each new drug approval. Manually updating and curating comprehensive databases is a continuous, resource-intensive challenge. 2. **Alert Fatigue:** Overly sensitive or non-specific alerts can lead clinicians to ignore warnings, potentially missing a genuine, high-risk interaction [2]. 3. **Lack of Context:** Traditional systems often fail to account for patient-specific factors such as genetics, comorbidities, renal or hepatic function, and concurrent non-prescription supplements, which can significantly alter a drug's metabolism and interaction profile.

How AI Revolutionizes Medication Interaction Checks

AI, particularly Machine Learning (ML) and Large Language Models (LLMs), addresses these limitations by leveraging advanced computational power to analyze vast, heterogeneous datasets, including electronic health records

(EHRs), genomic data, scientific literature, and chemical structures [3].

1. Predictive Modeling for Novel Interactions

Unlike rule-based systems that only flag *known* interactions, AI models can **predict novel DDIs** before they are clinically observed. By analyzing drug properties, target proteins, metabolic pathways, and side-effect profiles, ML algorithms can identify subtle patterns indicative of a potential interaction.

| AI Technique | Application in DDI Checks | Benefit | | :--- | :--- | :--- | | **Machine Learning (ML)** | Predicts DDI likelihood based on chemical structure and biological targets. | Identifies *novel* interactions not yet in databases. | | **Natural Language Processing (NLP)** | Extracts DDI information from unstructured text (e.g., clinical notes, literature). | Keeps DDI knowledge base current and comprehensive. | | **Deep Learning (DL)** | Analyzes complex, multi-modal data (genomics, EHRs, lab results). | Provides highly personalized, context-aware risk scores. |

2. Context-Aware and Personalized Risk Assessment

The most significant advancement is the shift from a binary "interaction/no interaction" alert to a **personalized risk score**. AI models can integrate real-time patient data—such as recent lab results (e.g., INR for warfarin), age, weight, and genetic markers (e.g., CYP450 enzyme polymorphisms)—to calculate the *severity* and *probability* of an adverse event for that specific individual [4]. This personalization drastically reduces alert fatigue by prioritizing only the most clinically relevant warnings.

3. Optimizing Alert Systems

AI is being used to optimize the alert presentation itself. By analyzing clinician response patterns, AI can learn which alerts are most often ignored and adjust the sensitivity or presentation style. For example, a system might use a less intrusive notification for a low-risk interaction but demand a mandatory hard stop for a high-risk, life-threatening combination. This is crucial for maintaining the utility of clinical decision support systems (CDSS) [2].

Practical Implementation and Future Outlook

For professionals and institutions looking to implement AI-driven DDI checks, the process involves integrating specialized AI platforms with existing EHR and pharmacy systems. These platforms often operate in the background, providing enhanced data to the CDSS.

The future of AI in medication safety is moving toward fully integrated, **proactive systems**. This includes using AI to guide drug discovery to minimize DDI potential from the outset and employing LLMs to synthesize complex clinical scenarios and provide immediate, evidence-based recommendations to prescribers [5].

The successful deployment of these technologies requires a deep understanding of both clinical pharmacology and advanced computational methods. For more in-depth analysis on this topic, the resources at www.rasitdinc.com provide expert commentary

and further professional insight into the intersection of digital health, AI, and patient safety.

**

References

[1] Graafsma, J., et al. (2024). The use of artificial intelligence to optimize medication alerts in a hospital setting. BMC Medical Informatics and Decision Making*. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11105146/] (https://pmc.ncbi.nlm.nih.gov/articles/PMC11105146/) [2] Domián, B. M., et al. (2025). Comparative evaluation of artificial intelligence platforms against conventional drug-drug interaction screening databases.* Digital Health and Patient Safety*. [https://www.sciencedirect.com/science/article/pii/S2667276625000964] (https://www.sciencedirect.com/science/article/pii/S2667276625000964) [3] Huang, W., et al. (2025). Advancing drug-drug interactions research: integrating AI and medication management tools*. Frontiers in Pharmacology*. [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1618701/fu (https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1618701/fu [4] Al-Ashwal, F. Y., et al. (2023). Evaluating the sensitivity, specificity, and accuracy of ChatGPT-3.5, ChatGPT-4, Bing AI, and Bard in predicting drug-drug interactions.* Drug, Healthcare and Patient Safety*. [https://www.dovepress.com/evaluating-the-sensitivity-specificity-and-accuracy-of-chatgpt-35-chat-peer-reviewed-fulltext-article-DHPS] (https://www.dovepress.com/evaluating-the-sensitivity-specificity-and-accuracy-of-chatgpt-35-chat-peer-reviewed-fulltext-article-DHPS) [5] Ong, J. C. L., et al. (2025). A scoping review on generative AI and large language models in clinical decision support.* npj Digital Medicine*. [https://www.nature.com/articles/s41746-025-01565-7] (https://www.nature.com/articles/s41746-025-01565-7)
